Company Overview

Genmab A/S is a Danish biotechnology company focused on the discovery, development, and commercialization of antibody-based therapeutics for cancer and other serious diseases. The company operates primarily in the global biopharmaceutical and oncology sectors, with a business model centered on proprietary antibody technologies, strategic drug development partnerships, milestone payments, royalties, and product sales. Genmab is best known for its role in developing antibody therapies targeting hematologic malignancies and solid tumors, including products commercialized with large pharmaceutical partners.

The company’s primary revenue drivers include royalties from marketed therapies, collaboration revenue, and sales from proprietary products. Key products associated with Genmab include Darzalex (daratumumab), developed with Janssen Biotech, and Epkinly/Tepkinly (epcoritamab), developed with AbbVie. Genmab also advances wholly owned and partnered oncology pipelines using proprietary technology platforms such as DuoBody, HexaBody, and DuoHexaBody. Founded in 1999 and headquartered in Copenhagen, Genmab evolved from a research-focused antibody developer into a commercial-stage biotechnology company with a broad global oncology portfolio and multiple late-stage clinical assets.

Business Operations

Genmab organizes its business around antibody therapeutics research, clinical development, strategic collaborations, and commercialization activities. The company generates revenue through royalty streams, licensing agreements, milestone payments, and direct product-related revenue. Its core technological assets include the proprietary DuoBody, HexaBody, and DuoHexaBody antibody engineering platforms, which are used internally and through external collaborations to create next-generation cancer therapies. The company maintains substantial research and development operations focused on immuno-oncology and antibody-based innovation.

Internationally, Genmab operates through research, clinical, and commercial activities across Europe, North America, and parts of Asia-Pacific. Strategic partnerships are central to its operating model, including collaborations with Johnson & Johnson/Janssen Biotech, AbbVie, BioNTech, and other biotechnology and pharmaceutical companies. The company also maintains subsidiaries and operational entities in countries including the United States, Netherlands, and Japan, supporting global clinical trials, regulatory activities, and commercialization efforts.

Strategic Position & Investments

Genmab’s strategic direction emphasizes expanding its proprietary oncology pipeline while increasing its transition toward a fully integrated biotechnology company with commercial capabilities. The company has invested heavily in late-stage oncology programs, bispecific antibody technologies, and next-generation immune therapies. Its development strategy combines internal innovation with co-development partnerships that reduce commercialization risk while expanding market reach. A significant portion of its long-term strategy focuses on advancing differentiated antibody platforms capable of targeting difficult-to-treat cancers.

Major strategic assets include partnerships around Darzalex and epcoritamab, as well as investments in proprietary candidates such as tisotumab vedotin and acasunlimab. Genmab has also expanded manufacturing, translational research, and artificial intelligence-enabled drug discovery capabilities through collaborations and technology investments. The company continues to prioritize hematologic malignancies and solid tumors while exploring emerging areas of antibody-drug conjugates, bispecific antibodies, and immune modulation.

Geographic Footprint

Genmab is headquartered in Copenhagen, Denmark, and maintains a significant operational presence in the United States, particularly through offices and research activities in New Jersey and other biotechnology hubs. The company’s therapies are marketed globally through commercial partners, giving it exposure to major pharmaceutical markets across North America, Europe, Asia-Pacific, and selected emerging markets.

Its international footprint is reinforced by multinational clinical trial programs, cross-border licensing agreements, and collaborations with major pharmaceutical companies. Genmab’s products and development programs have regulatory and commercial relevance in markets including the United States, European Union, Japan, and additional international oncology markets where partnered therapies have received approvals or are under regulatory review.

Leadership & Governance

Genmab’s leadership structure combines biotechnology research expertise with commercial pharmaceutical experience. The company has historically emphasized long-term scientific innovation, disciplined capital allocation, and partnership-driven growth. Governance is overseen by a board of directors and executive management team with backgrounds spanning oncology drug development, global commercialization, finance, and pharmaceutical operations.

Key executives include:

• Jan van de Winkel – President and Chief Executive Officer
• Anthony Mancini – Executive Vice President and Chief Operating Officer
• Ulf Wiinberg – Chair of the Board of Directors
• Judith Klimovsky – Executive Vice President and Chief Development Officer
• Ying Huang – Executive Vice President and Chief Technical Officer
• Niels Christian Nielsen – Executive Vice President and Chief Financial Officer

The company’s leadership philosophy has consistently emphasized scientific differentiation, strategic collaboration, and the development of proprietary technologies capable of supporting long-term oncology innovation and sustainable revenue growth.